about
Efficient co-delivery of immiscible hydrophilic/hydrophobic chemotherapeutics by lipid emulsions for improved treatment of cancer.Ion-exchange resins: carrying drug delivery forward.Formulation aspects in the development of osmotically controlled oral drug delivery systems.Hydrogels: from controlled release to pH-responsive drug delivery.Development of intramammary delivery systems containing lasalocid for the treatment of bovine mastitis: impact of solubility improvement on safety, efficacy, and milk distribution in dairy cattle.Permeability issues in nasal drug delivery.Bioadhesive microspheres as a controlled drug delivery system.Osmotic pumps in drug delivery.Quality, safety and efficacy in the 'off-label' use of medicines.Microbicide delivery: formulation technologies and strategies.Electrochemically controlled drug delivery based on intrinsically conducting polymers.Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets.Targeting of nanoparticles in cancer: drug delivery and diagnostics.An overview on chemical derivatization and stability aspects of selected avermectin derivatives.Analytical profile of moxidectin.Non-vascular drug eluting stents as localized controlled drug delivery platform: preclinical and clinical experience.New Zealand's drug development industry.Multifunctional iron bound lactoferrin and nanomedicinal approaches to enhance its bioactive functions.Daptomycin: Physicochemical, Analytical, and Pharmacological Properties.A birth control vaccine is on the horizon for family planning.Investigation of the biodistribution, breakdown and excretion of delta inulin adjuvant.Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in vivo evaluation.Folic acid-grafted bovine serum albumin decorated graphene oxide: An efficient drug carrier for targeted cancer therapy.Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide.Development of Topical Delivery Systems for Flightless Neutralizing Antibody.In Vitro and In Vivo Assessment of Docetaxel Formulation Developed for Esophageal Stents.Key Considerations in Designing Oral Drug Delivery Systems for Dogs.Conducting polymers with defined micro- or nanostructures for drug delivery.Development of Intramammary Drug Delivery Systems: Novel In Vitro Release Method.Development of PIK-75 nanosuspension formulation with enhanced delivery efficiency and cytotoxicity for targeted anti-cancer therapy.Evaluation of mucoadhesive coatings of chitosan and thiolated chitosan for the colonic delivery of microencapsulated probiotic bacteria.Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells.Extemporaneous compounding in veterinary practice: a New Zealand perspective.Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.In vitro comparison of the dermal penetration of three different topical formulations containing lasalocid.Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent.Development of an improved Streptococcus uberis experimental mastitis challenge model using different doses and strains in lactating dairy cows.Formulation development and dissolution rate enhancement of efavirenz by solid dispersion systems.Inhibition of the growth and development of asexual and sexual stages of drug-sensitive and resistant strains of the human malaria parasite Plasmodium falciparum by Neem (Azadirachta indica) fractions.Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion.
P50
Q33563252-6E546B01-43F1-46FA-B52A-A77C14ABBB23Q34346641-05BA10C8-355A-4855-8F95-89662B41B286Q34537579-036CE187-D38F-4D14-B7C4-B9EA5D054CA0Q34669619-BEAC7907-1F1B-4A99-B85D-A8229D3CA000Q35026160-3E89A34C-9EAE-4D6A-87CE-1D3A3A8944A9Q35053139-245D2803-4F39-42B6-931E-C8070EEDE2AFQ35097725-7A7FB445-8872-4421-AA22-2344EC25E93AQ36013739-2CD3B40F-6080-4A35-A293-D0BBB594804CQ37239445-B75834DD-FE14-4556-A5AC-D997E06E0429Q37447846-E4C1ABB9-68AB-40E9-B5E5-44551A59D47DQ37722842-2D20A69A-6247-408D-BACA-85A8D07C1164Q37812428-C697F4CE-D442-4EE4-BCE2-899E48C2AE53Q37942288-8F3451BC-3121-4C3D-84ED-E51AB18D5CDAQ38032080-4DAF2523-4E5C-4C23-96FF-62ED1ECB3AE2Q38106293-F760F415-62A9-494E-9ABB-FB79C1B4F384Q38130090-664363EB-D47E-4799-97C2-738256112A56Q38142696-2ECDB35C-2D3B-409B-B46C-25CBD8CFA5CEQ38504324-60857337-5074-486C-8950-2FB6514996B0Q38505691-067F6382-4BB7-4FB6-B6F9-D3F108AF4E9DQ38573702-94E523C3-43BC-42D1-AEF4-1F5CE89C1AE8Q38662873-3B4972C6-F85C-47D9-9315-6944582433C2Q38699643-D1ECED78-4242-4A49-9623-4FF7C360E63EQ38727426-5219D325-3503-4B36-ADD1-6D2441C7930DQ38738510-966CA0F5-9F77-4297-AEC5-A51CAF7687D3Q38740695-CA267D04-68AF-44C0-B749-8677EC0A5C33Q38792672-F414C53B-AA37-444D-9A7C-BF548B14F027Q38801524-99A2E868-27E0-4750-BC1B-2A26F3FFAFE5Q38978029-5172BEA2-01D4-4F4D-9923-22878F65B560Q39153401-1E57D86F-E693-42C5-85CF-2839C04AFBCFQ39158133-3D0A132C-A01D-47E7-9F60-A1B79F1F8387Q39322663-A8D9C14D-8510-4C20-AB91-441F9FCDD044Q39338877-97DC5C17-188C-4EEB-BF76-58FEED72CE2CQ39442163-0AA94976-75F3-45DA-8C02-BA81DA4FEF79Q40066351-536C92CE-7DF2-4F4A-A0EA-1DFD8FF8E90FQ40226860-CB000080-F921-48C7-8A25-40CC10892CBCQ40431656-428500CE-F14F-4C76-91AB-E995F9E1BCC7Q41100796-4C072636-F15E-4EEC-975D-FCC758EEF4CCQ41848183-04C1197B-0561-4894-B5AB-3D5C0F480314Q41925973-61773F1C-A00D-4F16-B975-56966A6CA9B0Q43281343-B10B0F35-F29B-4206-A178-26CB1F0534E1
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Sanjay Garg
@ast
Sanjay Garg
@en
Sanjay Garg
@es
Sanjay Garg
@nl
Sanjay Garg
@sl
সঞ্জয় গর্গ
@bn
type
label
Sanjay Garg
@ast
Sanjay Garg
@en
Sanjay Garg
@es
Sanjay Garg
@nl
Sanjay Garg
@sl
সঞ্জয় গর্গ
@bn
prefLabel
Sanjay Garg
@ast
Sanjay Garg
@en
Sanjay Garg
@es
Sanjay Garg
@nl
Sanjay Garg
@sl
সঞ্জয় গর্গ
@bn
P108
P214
P1053
B-2516-2012
P106
P108
P1153
7401717311
P21
P214
P31
P3829
P496
0000-0001-7253-2629
P569
2000-01-01T00:00:00Z
P735
P7859
viaf-305773223